Andrew Komjathy - Jun 2, 2023 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role
Chief Commercial Officer
Signature
/s/ Ben Harshbarger, as attorney-in-fact for Andrew Komjathy
Stock symbol
ATXS
Transactions as of
Jun 2, 2023
Transactions value $
$0
Form type
4
Date filed
6/6/2023, 08:07 AM
Previous filing
Mar 3, 2022
Next filing
Feb 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATXS Stock Option (Right to Buy) Award $0 +80K $0.00 80K Jun 2, 2023 Common Stock 80K $13.36 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the "Company") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the "Stock Plan Amendment Proposal"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023.
F2 This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 80,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments.

Remarks:

Exhibit 24 - Power of Attorney